Nazari, S., Poustforoosh, A., Paul, P., Kukreti, R., Tavakkoli, M., Saso, L., Firuzi, O., Moosavi, F, c-MET tyrosine kinase inhibitors reverse drug resistance mediated by the ATP-binding cassette transporter B1 (ABCB1) in cancer cells. Jun 2025

 

Mohammadi, S., Mortazavia, M., Poustforoosh, A., Moosavi, F., Saso, L., Edraki, N., Firuzi, O., Novel spiroisatin-pyranopyrazole hybrids as anticancer agents with TrkC inhibitory potential. 2025

 

Moosavi, F., Divar, M., Khabnadideh, S., Tavakkoli, M., Mohabbati, M., Saso, L., Poustforoosh, A., Firuzi, O., Spiroindoline quinazolinedione derivatives as inhibitors of P-glycoprotein: potential agents for overcoming multidrug resistance in cancer therapy. 2025

 

Moosavi, F., Firoozi, R., Tavakkoli, M., Nazari, S., Alipour, A., Firuzi, O., Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells. Apr 2025

 

 Eskandari, M., Moosavi, F., Nazari, S., Mardaneh, P., Poustforoosh, A., Zargari, F., Mohabbati, M., Saso, L., Edraki, N., Firuzi, O., N-ethyl morpholine-deca hydroacridine 1, 8-diones as novel P-gp inhibitors and multidrug resistance reversal agents in cancer cells. Mar 2025

 

Nazari, S., Mosaffa, F., Poustforoosh, A., Mortazavi, M., Saso, L., Firuzi, O., Moosavi, F. "Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.Toxicol. Appl. Pharmacol.2024 15:116866 (2024).

 

S.Ranjbar., F.Faramin Lashkarian ., M. Khoshneviszadeh ., F. Moosavi., A. Sakhteman ., F.Zargari ., L.Saso ., O.Firuzi ., N.Edraki. ۵-Oxohexahydroquinolines bearing ۴-pyridyl methyl carboxylate as P-glycoprotein inhibitors and multidrug resistance reversal agents in cancer cells. Journal of Molecular Structure. Volume 1285, 5 August 2023

 

Divar, M.,Edraki, N., Damghani, T., Moosavi, F., Mohabbati, M., Alipour, A., Pirhadi, S., Saso, L., Khabnadideh, S., Firuzi .,O. Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors. Bioorganic and Medicinal Chemistry. Volume 9015 July 2023 Article number 117367

 

M.Mortazavi, M. Divar, T. Damghani, F.Moosavi, L.Saso, S.Pirhadi, M.Khoshneviszadeh, N.Edraki, O.Firuzi. Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. Frontiers in Chemistry. 2022

 

 Mortazavi M., Moosavi F., , Martini M., Giovannetti E., Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer.Critical Reviews in Oncology/Hematology.2022

 

Haghighijoo Z., Zamani L., Moosavi F., Emami S. Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review. European Journal of Medicinal Chemistry. Volume 2275 - January 2022

 

Damghani T., Moosavi F., Khoshneviszadeh M., Mortazavi M., Pirhadi S., Kayani Z., Saso L., Edraki N., Firuzi O. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. Scientific Reports. Volume ۱۱, Issue ۱, December 2121, Article number 3644.

 

Moosavi F., Giovannetti E., Peters G.J., Firuzi O., Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology. Volume 160, April 2021, Article number 103234.

 

Moosavi F., Ebadi A., Mohabbati M., Damghani T., Mortazavi M., Miri R., Firuzi O. Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives. European Journal of Pharmacology. Volume 894, 5 March 2021, Article number 173850.

 

 

Damghani T., Moosavi F., Khoshneviszadeh M., Mortazavi M., Pirhadi S., Kayani Z., Saso L., Edraki N., Firuzi O. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. Scientific Reports. Volume ۱۱, Issue ۱, December 2021, Article number 3644.

 

Moosavi, F. Hosseini, R. Rajaian, H. Silva, T. Magalhães, E. Silva, D. Soares, P. Saso, L. Edraki, N. Miri, R. Borges, F. Firuzi, O. 2017 . Derivatives of caffeic acid, a natural antioxidant, as the basis for the discovery of novel nonpeptidic neurotrophic agents. Bioorganic & Medicinal Chemistry. 25(12):3235-3246.

 

Hosseini, R. Moosavi, F. Rajaian, H. Silva, T. Magalhães, E. Silva, D. Soares, P. Saso, L. Edraki, N. Miri, R. Borges, F. Firuzi, O .2016. Discovery of neurotrophic agents based on hydroxycinnamic acid scaffold. Chemical Biology & Drug Design. 88(6):926-937.

 

Moosavi, F. Hosseini, R. Saso, L. Firuzi, O. 2016. Modulation of neurotrophic signaling pathways by polyphenols. Drug Design, Development and Therapy, 10:23-42.

 

Mohsenzadeh, S. Esmaeili۱, M. Moosawi, F. Shahrtash, M. Saffari, M. Mohabatkar, H. 2011. Plant glutathione S-transferase classification, structure and evolution. African Journal of Biotechnology, 10(42), 8160-8165.

 

Moosawi, F. Mohabatkar, H. Mohsenzadeh, S.2011. Analysis of synonymous codon usage bias and nucleotide and amino acid composition in 13 species of Flaviviridae. Journal of Cell and Molecular Research, 3 (1), 1-11.

 

Moosawi, F. Mohabatkar, H. Mohsenzadeh, S. 2010. Computational prediction of properties and analysis of molecular phylogenetics of polyketide synthases in three species of Actinomycetes. Medicinal Chemistry, 6, 100-107.

 

Moosavi, F. Mohabatkar, H. Mohsenzadeh, S. 2010. Computer-aided analysis of structural properties and epitopes of Iranian HPV-16 E۷ oncoprotein. Interdisciplinary Sciences: Computational Life Sciences, 2(4), 367-372.